Pipeline

Our pipeline shows the progress we and our partners are making on products in development for priority infectious diseases. For an explanation of development phases, visit our clinical development page.

HIV vaccine & antibody candidates

HIV
Candidate name

eOD-GT8 60mer mRNA + Core-g28v2 60mer mRNA

HIV

Partners

Bill & Melinda Gates Foundation; Collaboration for AIDS Vaccine Discovery Vaccine Immunology Statistical Center; Duke University; Emory University; Fred Hutchinson Cancer Center; George Washington University; Moderna; Scripps Research; United States Institutes of Health Vaccine Research Center; University of Texas San Antonio

Phase 1
Clinical trial info
Candidate name

eOD-GT8 60mer mRNA

HIV

Partners

Aurum Institute (Tembisa, South Africa); Bill & Melinda Gates Foundation; Center for Family Health Research (Kigali, Rwanda); Moderna; Scripps Research; United States Agency for International Development

Phase 1
Clinical trial info
Candidate name

rVSVΔG-Env-HIV

HIV

Partners

Government of Japan

Pre-clinical
Candidate name

Triple antibody combination product

HIV

Partners

Scripps Research; United States Agency for International Development; United States National Institutes of Health and its clinical trial networks; University of Oslo

Pre-clinical

Emerging infectious diseases vaccine candidates

Lassa Fever
Ebola Sudan Virus
Marburg Virus
COVID-19
Candidate name

rVSVΔG-LASV-GPC

Lassa Fever

Partners

Batavia Biosciences; Brigham and Women’s Hospital (Phase 1); Charles River Laboratories; Coalition for Epidemic Preparedness; East West Medical Research Institute Liberia (Phase 1); EpiCentre; European & Developing Countries Clinical Trials Partnership; George Washington University (Phase 1); Imperial College London; IQVIA; La Jolla Institute for Immunology; Kenema Government Hospital; Merck Advisory Group; NeoGenomics Laboratories; Noguchi Memorial Institute for Medical Research, Ghana (Phase 2a); PREVAIL JFK Hospital Liberia (Phase 2a); PREVAIL Redemption Hospital (Phase 1); Public Health Agency of Canada; Seattle Children’s Research Institute; The George Washington University; Tulane University; Walter Reed Program, Nigeria (Phase 2a)

Phase 1
Clinical trial info
Candidate name

rVSV∆G-SUDV-GP

Ebola Sudan Virus

Partners

Batavia Biosciences; Biomedical Advanced Research and Development Authority (BARDA); BioReliance; Boston University’s National Emerging Infectious Diseases Laboratories; Charles River Laboratories; Imperial College London; IQVIA; La Jolla Institute for Immunology; Merck Advisory Group; NeoGenomics Laboratories; Public Health Agency of Canada; Seattle Children’s Research Institute; Tulane University; University of Texas Medical Branch at Galveston; Viral Hemorrhagic Fever Consortium

Phase 1
Clinical trial info
Candidate name

rVSV∆G-MARV-GP

Marburg Virus

Partners

Batavia Biosciences; Charles River Laboratories; Defense Threat Reduction Agency; Imperial College London; IQVIA; La Jolla Institute for Immunology; Merck Advisory Group; Public Health Agency of Canada; Seattle Children’s Research Institute; Texas Biomedical Research Institute; University of Texas Medical Branch at Galveston; Viral Hemorrhagic Fever Consortium

Pre-clinical
Candidate name

rVSV∆G-SARS-CoV-2

COVID-19

Partners

Batavia Biosciences; Boston University’s National Emerging Infectious Diseases Laboratory; Charles River Laboratories; Defense Threat Reduction Agency; Government of Japan; Imperial College London; Merck Advisory Group; Neogenomics Laboratories; PATH; Public Health Agency of Canada; University of North Carolina at Chapel Hill

Pre-clinical

Tuberculosis (TB) vaccine candidates

Tuberculosis
Candidate name

MTBVAC

Tuberculosis

Partners

Bill & Melinda Gates Foundation; Biofabri S.L.; Open Philanthropy; Universidad de Zaragoza

Phase 2
Candidate name

MTBVAC (People living with HIV)

Tuberculosis

Partners

Biofabri S.L., HIV Vaccine Trials Network; National Institute of Allergy and Infectious Diseases; South African Tuberculosis Vaccine Initiative; Universidad de Zaragoza

Phase 2
Clinical trial info
Candidate name

mRNA-encoded TB antigens

Tuberculosis

Partners

Moderna; Trudeau Institute; U.S. National Institute of Allergy and Infectious Diseases; U.S. National Institutes of Health; University of Georgia

Pre-clinical